Medtech Firm Nativis Appoints Ferguson Chief Scientific Officer

Nativis, a medical device company aiming to use ultra-low radio frequency energy to treat disease, has appointed Kenneth Ferguson chief scientific officer. Seattle-based Nativis is currently in clinical trials testing its medical device, Nativis Voyager, as a treatment for recurrent glioblastoma, a form of brain cancer. Before joining Nativis, Ferguson was chief development officer for Seattle biotech Omeros (NASDAQ: [[ticker:OMER]]). His experience also includes executive roles at VacTX and Icos, now a subsidiary of Eli Lilly (NYSE: [[ticker:LLY]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan